Breast, Prostate Cancer Common in Patients With COVID-19 and Cancer History
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
An analysis of the 2019 Global Burden of Disease Study offers insight into rates and risk factors for respiratory tract cancers globally, regionally, and nationally.
The method involves DELFI, an approach that can detect many abnormalities in cfDNA through genome-wide analysis of fragmentation patterns.
Turkish researchers sought to measure the effects of this strategy on FTP, ABG, and quality of life in patients with lung cancer.
Exkivity (mobocertinib) is approved to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
The genomic-adjusted radiation dose (GARD) model predicts outcomes of radiotherapy.
Patient age, treatment center, and tumor size were associated with a lack of adherence.
The highest response rate observed with any therapy was 25%.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
Immune checkpoint inhibitors prolonged survival when compared with chemotherapy.